Tag: substrate reduction therapy
-

Sanofi’s Infilbray Wins FDA Approval for Neurological Symptoms of Type 3 Gaucher Disease
Sanofi’s Infilbray becomes the first FDA-approved treatment for neurological manifestations of Type 3 Gaucher disease. Explore its mechanism, Phase 3 findings and significance for patients.